Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,171,571 | $568,001,052 | -17% | 0.86% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 489,667 | $237,400,355 | +135% | 0.44% |
| 3. | Alyeska Investment Group Anand Parekh | 431,804 | $209,347,215 | +457% | 0.83% |
| 4. | Millennium Management Israel Englander | 309,935 | $150,262,687 | -1% | 0.08% |
| 5. | 277,000 | $134,295,140 | -21% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | $1,123,420.98 | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | $2,968,650.00 | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | $854,374.95 | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | $928,682.30 | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $424.69 | 52 | $22,083.88 | 23,281 | 2025-05-15 | Filing | |
| $505.86 | 400 | $202,344.00 | 4,831 | 2025-05-02 | Filing | |
| $510.00 | 3,231 | $1,647,810.00 | 23,281 | 2025-03-13 | Filing | |
| $500.00 | 3,298 | $1,649,000.00 | 51,671 | 2025-03-10 | Filing | |
| $499.99 | 3,242 | $1,620,967.58 | 51,239 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,533,308 | $13,833,749,349 | 2.24% | |
| 2. | 23,491,161 | $11,388,984,677 | 0.21% | |
| 3. | 21,782,933 | $10,560,801,400 | 0.22% | |
| 4. | 14,536,344 | $7,047,591,088 | 1.53% | |
| 5. | 11,788,657 | $5,715,376,687 | 0.24% |
News See All
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” first quarter 2025 investor letter.
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
15 Best Stocks to Buy According to Jim Simons' Renaissance Technologies
Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the "Quant King" of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative...
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript May 5, 2025Vertex Pharmaceuticals Incorporated misses on earnings expectations.
21 Stocks on Jim Cramer's Radar
“When you get a strong employment report like we did this morning, it does a lot of things that you need to know about. First, it takes a near-term recession kind of off the table.
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise
GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.